These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Improper use of selective COX-2 inhibitor NSAIDs]. Rocamora Batalla M; Vallano Ferraz A Aten Primaria; 2002 Feb; 29(2):122. PubMed ID: 11844430 [No Abstract] [Full Text] [Related]
4. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Perazella MA; Tray K Am J Med; 2001 Jul; 111(1):64-7. PubMed ID: 11448662 [No Abstract] [Full Text] [Related]
5. Arthritis. Should you be taking a COX-2 inhibitor? Harv Health Lett; 2001 Nov; 27(1):1-3. PubMed ID: 11724695 [No Abstract] [Full Text] [Related]
6. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex). Wynn RL Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547 [No Abstract] [Full Text] [Related]
7. [COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?]. Bannwarth B Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B79-84. PubMed ID: 11449148 [No Abstract] [Full Text] [Related]
8. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs. Atkinson HG Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146 [No Abstract] [Full Text] [Related]
15. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis. Ann Intern Med; 2003 May; 138(10):I39. PubMed ID: 12755582 [No Abstract] [Full Text] [Related]
16. COX-2 inhibitors: new drugs for the management of pain and inflammation. Hutchins V; Hutchins B Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847 [No Abstract] [Full Text] [Related]
17. The coxibs, selective inhibitors of cyclooxygenase-2. FitzGerald GA; Patrono C N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855 [No Abstract] [Full Text] [Related]
18. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789 [TBL] [Abstract][Full Text] [Related]
20. [Therapy with preferential and specific COX-2 inhibitors]. Stichtenoth DO; Frölich JC Internist (Berl); 2001 Mar; 42(3):421-6. PubMed ID: 11277028 [No Abstract] [Full Text] [Related] [Next] [New Search]